About AmpliPhi Biosciences (NYSEAMERICAN:APHB)
AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections. AmpliPhi Biosciences Corporation has a collaboration agreement and a license agreement with the University of Leicester; and a collaboration agreement with the Western Sydney Local Health District and the Westmead Institute for Medical Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:APHB
CUSIPN/A
Phone+1-804-8272524
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-2,050.00%
Return on Equity-31.85%
Return on Assets-21.63%
Miscellaneous
EmployeesN/A
Outstanding Shares16,460,000
AmpliPhi Biosciences (NYSEAMERICAN:APHB) Frequently Asked Questions
What is AmpliPhi Biosciences' stock symbol?
AmpliPhi Biosciences trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "APHB."
How were AmpliPhi Biosciences' earnings last quarter?
AmpliPhi Biosciences (NYSEAMERICAN:APHB) released its earnings results on Wednesday, March, 14th. The biotechnology company reported ($0.25) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.36) by $0.11. The biotechnology company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.03 million. AmpliPhi Biosciences had a negative return on equity of 31.85% and a negative net margin of 2,050.00%. View AmpliPhi Biosciences' Earnings History.
When is AmpliPhi Biosciences' next earnings date?
What price target have analysts set for APHB?
1 brokerages have issued 12-month price objectives for AmpliPhi Biosciences' stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate AmpliPhi Biosciences' share price to reach $6.00 in the next year. View Analyst Ratings for AmpliPhi Biosciences.
Are investors shorting AmpliPhi Biosciences?
AmpliPhi Biosciences saw a drop in short interest during the month of March. As of March 29th, there was short interest totalling 1,103,899 shares, a drop of 9.5% from the March 15th total of 1,219,178 shares. Based on an average daily trading volume, of 535,566 shares, the days-to-cover ratio is currently 2.1 days. Approximately 7.1% of the shares of the company are sold short.
Who are some of AmpliPhi Biosciences' key competitors?
Some companies that are related to AmpliPhi Biosciences include Arch Therapeutics (ARTH), AzurRx BioPharma (AZRX), Pure Bioscience (PURE), IntelGenx Technologies (IGXT), Omnicomm Systems (OMCM), Vaxart (VXRT), Vivus (VVUS), Celsion (CLSN), Presbia (LENS), Proteon Therapeutics (PRTO), ANGLE (AGL), ReNeuron (RNUGF), Capricor Therapeutics (CAPR), Evoke Pharma (EVOK), Cellect Biotechnology (APOP), PLx Pharma (PLXP), Chiasma (CHMA) and Soleno Therapeutics (SLNO).
Who are AmpliPhi Biosciences' key executives?
AmpliPhi Biosciences' management team includes the folowing people:
- Dr. Paul C. Grint, Chief Exec. Officer & Director (Age 60)
- Mr. Steven R. Martin, Sr. VP & CFO (Age 57)
- Dr. Igor P. Bilinsky Ph.D., Sr. VP & COO (Age 45)
- Mr. Michael Scott Salka, Consultant (Age 56)
- Dr. Alexander Gaidamaka Ph.D., D.V.M, VP of Chemistry, Manufacturing and Control
Has AmpliPhi Biosciences been receiving favorable news coverage?
News stories about APHB stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. AmpliPhi Biosciences earned a media sentiment score of 0.18 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 45.93 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are AmpliPhi Biosciences' major shareholders?
AmpliPhi Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include
SABBY MANAGEMENT, LLC
(7.78%). Company insiders that own AmpliPhi Biosciences stock include Jeremy Curnock Cook and Randal J Kirk. View Institutional Ownership Trends for AmpliPhi Biosciences.
How do I buy shares of AmpliPhi Biosciences?
Shares of APHB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AmpliPhi Biosciences' stock price today?
One share of APHB stock can currently be purchased for approximately $1.15.
How big of a company is AmpliPhi Biosciences?
AmpliPhi Biosciences has a market capitalization of $21.87 million.
How can I contact AmpliPhi Biosciences?
AmpliPhi Biosciences' mailing address is 3579 Valley Centre Drive, SAN DIEGO, CA 92130, United States. The biotechnology company can be reached via phone at +1-804-8272524.
MarketBeat Community Rating for AmpliPhi Biosciences (APHB)
MarketBeat's community ratings are surveys of what our community members think about AmpliPhi Biosciences and other stocks. Vote "Outperform" if you believe APHB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APHB will underperform the S&P 500 over the long term. You may vote once every thirty days.
AmpliPhi Biosciences (NYSEAMERICAN:APHB) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for AmpliPhi Biosciences in the last 12 months. Their average twelve-month price target is $6.00, suggesting that the stock has a possible upside of 421.74%. The high price target for APHB is $6.00 and the low price target for APHB is $6.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.00 | $6.00 | $6.00 | $7.50 |
| Price Target Upside: | 421.74% upside | 282.17% upside | 450.46% upside | 724.18% upside |
AmpliPhi Biosciences (NYSEAMERICAN:APHB) Consensus Price Target History
AmpliPhi Biosciences (NYSEAMERICAN:APHB) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
| 3/15/2018 | HC Wainwright | Set Price Target | Buy | $6.00 |  |
| 1/24/2017 | Roth Capital | Reiterated Rating | Buy | | |
(Data available from 4/23/2016 forward)
AmpliPhi Biosciences (NYSEAMERICAN:APHB) Earnings History and Estimates Chart
AmpliPhi Biosciences (NYSEAMERICAN APHB) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/14/2018 | | | | | | | N/A | |
| 3/14/2018 | Q4 2017 | ($0.36) | ($0.25) | $0.03 million | $0.02 million | View | N/A | |
| 11/14/2017 | Q3 2017 | ($0.46) | ($0.09) | $0.03 million | $0.04 million | View | N/A | |
| 8/14/2017 | Q2 2017 | ($0.80) | ($0.78) | | $0.03 million | View | N/A | |
| 5/15/2017 | Q1 2017 | ($8.20) | ($1.94) | $0.10 million | $0.03 million | View | N/A | |
| 3/27/2017 | Q4 2016 | ($3.30) | ($3.20) | $0.10 million | $0.02 million | View | N/A | |
| 11/10/2016 | Q3 2016 | ($3.80) | ($3.20) | $0.10 million | $0.03 million | View | N/A | |
| 8/15/2016 | Q216 | ($0.66) | ($0.78) | $0.10 million | $0.10 million | View | Listen | |
| 5/12/2016 | Q116 | ($0.68) | ($0.82) | $0.11 million | $0.11 million | View | N/A | |
| 3/30/2016 | Q415 | ($0.40) | ($0.43) | $0.12 million | $0.13 million | View | N/A | |
| 11/16/2015 | Q3 2015 | ($2.00) | ($3.00) | $0.10 million | $0.14 million | View | N/A | |
| 8/13/2015 | Q2 2015 | ($7.50) | ($5.70) | | $0.10 million | View | N/A | |
| 5/15/2015 | Q1 2015 | ($5.00) | ($5.00) | | $0.10 million | View | N/A | |
| 4/15/2015 | Q4 2014 | ($5.00) | ($5.00) | | $0.10 million | View | N/A | |
| 11/18/2014 | | ($0.02) | $0.06 | | | View | N/A | |
| 9/24/2014 | | ($0.02) | ($0.01) | | | View | N/A | |
| 9/12/2014 | Q2 2014 | ($10.00) | ($5.00) | | $0.31 million | View | N/A | |
| 5/20/2014 | Q1 2014 | ($10.00) | ($30.00) | | | View | N/A | |
| 6/1/2010 | Q4 2009 | | $42.50 | | | View | N/A | |
| 11/16/2009 | Q3 2009 | | $16.00 | | | View | N/A | |
| 8/12/2009 | Q2 2009 | | $345.50 | | | View | N/A | |
| 5/7/2009 | Q1 2009 | | ($35.50) | | | View | N/A | |
| 3/31/2009 | Q4 2008 | | ($64.00) | | | View | N/A | |
| 8/6/2008 | Q2 2008 | ($85.00) | ($95.50) | | | View | N/A | |
| 5/7/2008 | Q1 2008 | ($150.00) | ($81.00) | | | View | N/A | |
| 3/25/2008 | Q4 2007 | | ($94.00) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
AmpliPhi Biosciences (NYSEAMERICAN:APHB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
AmpliPhi Biosciences (NYSEAMERICAN APHB) Insider Trading and Institutional Ownership History
AmpliPhi Biosciences (NYSEAMERICAN APHB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/22/2018 | Jeremy Curnock Cook | Director | Buy | 354,315 | $1.54 | $545,645.10 | 330 | |
| 12/29/2016 | Randal J Kirk | Major Shareholder | Sell | 177,020 | $0.48 | $84,969.60 | | |
| 4/8/2016 | Jeremy Curnock Cook | Director | Buy | 239,753 | $2.36 | $565,817.08 | | |
| 10/6/2015 | Louis Drapeau | Director | Buy | 10,000 | $4.39 | $43,900.00 | 10,000 | |
| 10/5/2015 | Michael Scott Salka | CEO | Buy | 4,200 | $4.75 | $19,950.00 | 4,200 | |
| 10/5/2015 | Wendy S Johnson | Insider | Buy | 1,000 | $4.43 | $4,430.00 | 1,000 | |
| 3/16/2015 | Randal J Kirk | Major Shareholder | Buy | 13,939,392 | $0.17 | $2,369,696.64 | | |
(Data available from 1/1/2013 forward)
AmpliPhi Biosciences (NYSEAMERICAN APHB) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | AmpliPhi Biosciences (APHB) Short Interest Down 9.5% in March
www.americanbankingnews.com - April 11 at 2:04 AM |
 | AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Study at ISHLT Annual Meeting
finance.yahoo.com - April 3 at 8:23 AM |
| HC Wainwright Increases AmpliPhi Biosciences (APHB) Price Target to $6.00
www.americanbankingnews.com - March 27 at 6:48 PM |
 | Tuesday 3/27 Insider Buying Report: FLL, APHB
www.nasdaq.com - March 27 at 5:14 PM |
 | Form 4 AmpliPhi Biosciences For: Jun 21 Filed by: COOK JEREMY CURNOCK
www.streetinsider.com - March 27 at 5:14 PM |
| AmpliPhi Biosciences (APHB) Director Buys $345,328.40 in Stock
www.americanbankingnews.com - March 26 at 10:26 PM |
| AmpliPhi Biosciences (APHB) Director Jeremy Curnock Cook Purchases 354,315 Shares
www.americanbankingnews.com - March 26 at 10:08 PM |
| Short Interest in AmpliPhi Biosciences (APHB) Increases By 16.7%
www.americanbankingnews.com - March 26 at 6:54 PM |
| APHB: Expecting to Meet with FDA in mid-2018 to Determine Regulatory Path Forward
finance.yahoo.com - March 26 at 5:18 PM |
 | AmpliPhi Biosciences Announces Closing of Registered Direct Offering of Common Stock - Business Wire (press release)
www.businesswire.com - March 23 at 8:18 AM |
| AmpliPhi Biosciences Announces Closing of Registered Direct Offering of Common Stock
finance.yahoo.com - March 22 at 5:36 PM |
 | AmpliPhi Bio commences direct stock offering at $1.10; shares down 16% premarket
seekingalpha.com - March 20 at 5:18 PM |
| AmpliPhi Biosciences (APHB) Announces Registered Direct Offering of Common Stock
www.streetinsider.com - March 20 at 5:18 PM |
| AmpliPhi to Collaborate with Western Sydney Local Health District and Westmead Institute for Medical Research on ... - Business Wire (press release)
www.businesswire.com - March 20 at 8:27 AM |
| AmpliPhi Biosciences (APHB) Announces Registered Direct Offering of Common Stock - StreetInsider.com
www.streetinsider.com - March 20 at 8:27 AM |
| AmpliPhi Biosciences Announces Registered Direct Offering of Common Stock
finance.yahoo.com - March 20 at 8:27 AM |
| AmpliPhi Bio expands compassionate use for AB-SA01 and AB-PA01 in Australia
seekingalpha.com - March 19 at 5:18 PM |
| AmpliPhi to Collaborate with Western Sydney Local Health District and Westmead Institute for Medical Research on Expanded Access for Investigational Bacteriophage Therapeutics AB-SA01 and AB-PA01
finance.yahoo.com - March 19 at 5:18 PM |
| AmpliPhi Biosciences beats by $0.11, misses on revenue
seekingalpha.com - March 16 at 6:30 PM |
| AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2017 Financial Results and Business Highlights - Business Wire (press release)
www.businesswire.com - March 16 at 8:19 AM |
| HC Wainwright Analysts Give Ampliphi Biosciences (APHB) a $6.00 Price Target
www.americanbankingnews.com - March 15 at 4:54 PM |
| AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2017 Financial Results and Business Highlights
finance.yahoo.com - March 14 at 7:07 PM |
| AmpliPhi to collaborate with the U.S. Department of Veterans Affairs on expanded access for AB-SA01 and AB-PA01
seekingalpha.com - March 13 at 7:17 PM |
| AmpliPhi to Collaborate with the US Department of Veterans Affairs on Expanded Access for Investigational ... - Business Wire (press release)
www.businesswire.com - March 13 at 8:25 AM |
| AmpliPhi Biosciences (APHB) Reports Agreement with US Dept of Veteran Affairs to Expand Access for Investigational ... - StreetInsider.com
www.streetinsider.com - March 13 at 8:25 AM |
| AmpliPhi to Collaborate with the U.S. Department of Veterans Affairs on Expanded Access for Investigational Bacteriophage Therapeutics AB-SA01 and AB-PA01
finance.yahoo.com - March 13 at 8:25 AM |
| Wired News – AmpliPhi Biosciences Presents Pre-Clinical Data Validating AB-PA01’s Efficacy in Reducing Biofilm in Pseudomonas Aeruginosa Infections
finance.yahoo.com - March 13 at 8:25 AM |
| Ampliphi Biosciences Corp (APHB) Short Interest Up 9.7% in February
www.americanbankingnews.com - March 9 at 6:22 PM |
| AmpliPhi Biosciences Announces Presentation of Preclinical Data Demonstrating that AB-PA01 Reduces Biofilm in ... - Business Wire (press release)
www.businesswire.com - March 9 at 8:20 AM |
| AmpliPhi Biosciences (APHB) Announces Presentation of Preclinical Data on AB-PA01 - StreetInsider.com
www.streetinsider.com - March 9 at 8:20 AM |
| AmpliPhi Biosciences Announces Presentation of Preclinical Data Demonstrating that AB-PA01 Reduces Biofilm in Pseudomonas aeruginosa In Vivo Model
finance.yahoo.com - March 9 at 8:20 AM |
 | Pre-Market Technical Scan on Biotech Equities -- Amicus Therapeutics, Ampio Pharmaceuticals, AmpliPhi Biosciences ... - PR Newswire (press release)
www.prnewswire.com - March 6 at 8:15 AM |
| Ampliphi Biosciences Corp (APHB) Short Interest Down 18.7% in January
www.americanbankingnews.com - February 9 at 6:58 PM |
| Ampliphi Biosciences Corp (APHB) Sees Large Increase in Short Interest
www.americanbankingnews.com - January 24 at 6:10 PM |
| Best High Growth AMEX Stocks This Week
finance.yahoo.com - January 21 at 5:16 PM |
| ALRN To Report Data In 1H18, DFFN On Watch, D-Day Awaits ARDM
www.nasdaq.com - January 11 at 9:08 AM |
| AmpliPhi Biosciences (APHB) Prices 4M Share Common Offering at $1/Sh
www.streetinsider.com - January 11 at 9:08 AM |
| Ampliphi Biosciences Corp (APHB) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - January 11 at 2:36 AM |
 | Mid-Morning Market Update: Markets Open Lower; Lennar Earnings Miss Expectations
www.benzinga.com - January 10 at 11:30 AM |
| LPCN Awaits FDA Panel Vote Today, APHB Slumps, BGNE Crosses $100 Again
www.nasdaq.com - January 10 at 8:58 AM |
| AmpliPhi Biosciences Announces Pricing of $4.0 Million Public Offering of Common Stock
finance.yahoo.com - January 10 at 8:58 AM |
| AmpliPhi Biosciences Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 9 at 6:06 PM |
| APHB: Reports Positive Interim Results for Expanded Access Program
finance.yahoo.com - January 5 at 11:43 AM |
| APHB Is A Good Shot, ASND Keeps Inching Along, SKLN Soars ... - Nasdaq
www.nasdaq.com - January 4 at 8:52 AM |
| AmpliPhi Biosciences (APHB) Reports Interim Results for Single-Patient Expanded Access Program Utilizing AB-SA01 and AB-PA01
www.streetinsider.com - January 3 at 4:18 PM |
| AmpliPhi Biosciences Announces Positive Interim Results for Single-Patient Expanded Access Program Utilizing AB-SA01 and AB-PA01
finance.yahoo.com - January 3 at 4:13 PM |
| AmpliPhi Biosciences to Present at Biotech Showcase 2018
finance.yahoo.com - January 2 at 4:51 PM |
| Ampliphi Biosciences Corp (APHB) Short Interest Down 11.5% in December
www.americanbankingnews.com - December 28 at 1:26 AM |
| Best NasdaqGM Growth Stocks
finance.yahoo.com - December 20 at 11:27 AM |
| Health Care Sector Update for 12/15/2017: APHB,SGRY,GLYC,ECYT,TTPH,CASC - Nasdaq
www.nasdaq.com - December 16 at 8:54 AM |
AmpliPhi Biosciences (NYSEAMERICAN:APHB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AmpliPhi Biosciences (NYSEAMERICAN:APHB) Income Statement, Balance Sheet and Cash Flow Statement
AmpliPhi Biosciences (NYSEAMERICAN APHB) Stock Chart for Monday, April, 23, 2018
Loading chart…
